# A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

> **NCT01812642** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 33 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** JNJ-37822681
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01812642
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01812642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01812642, "A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01812642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*